Video

The DAPA-HF trial was hailed as a landmark study at the congress when the SGLT2 inhibitor, dapagliflozin, was shown to have an extraordinarily significant result versus placebo in reducing death and hospitilisation in patients with heart failure and reduced ejection fraction, both in those with and those without diabetes. The study is discussed by Professor David Hare (Professor of Medicine, University of Melbourne; Clinical Cardiologist, Austin Health, Victoria, Australia)

New guidance on diabetes, pre-diabetes and cardiovascular disease from the European Society of Cardiology (in collaboration with the European Association for the Study of Diabetes) was announced at the Congress. So what’s new? We find out from Professor Naveed Sattar (Professor of Metabolic Medicine, Institute of Cardiovascular and Medical Sciences, University of Glasgow)

The AFIRE study has provided evidence for guidance, which has recommended that antiplatelet therapy can be stopped after one year in an antiplatelet/antiocoagulant combination therapy regime post-revascularisation. Professor Freek Verheugt (Professor of Cardiology, Heart-Lung Centre of the University Medical Centre of Nijmegen; Chairman of the Department of Cardiology, Hospital Onze Lieve Vrouwe Gasthuis, Amsterdam, The Netherlands) gives his thoughts on the implications of the study.

New European Society of Cardiology/European Atherosclerosis Guidelines on the management of dyslipidaemias were published at the Congress. Professor Alberico Catapano (Professor of Pharmacology, and Director of the Center of Epidemiology and Preventive Pharmacology, University of Milan, Italy) talks about the recommendations including new, more intensive goals for low-density lipoprotein cholesterol.

Results from the ongoing PURE study, a prospective, epidemiological study in over 200,000 people in 27 countries, were presented at the Congress They show, for the first time, that cardiovascular disease is no longer the leading cause of death in high-income countries but is still very high in medium- and low-income countries. Professor Raul Santos (President of the International Atherosclerosis Society; director of the Lipid Clinic at the Heart Institute (InCor); Associate Professor of the University of São Paulo Medical School, and Hospital Israelita Albert Einstein in São Paulo, Brazil) discusses some of the study insights.

Interactive clinical cases are a popular session at the Cardiorenal Forum Annual Scientific Meeting. We are pleased to bring you this interactive case on anticoagulation and chronic kidney disease from this year’s meeting, held in London on 5th October 2018. The case was presented by Consultant Nephrologist, Dr Charles Ferro (University Hospitals, Birmingham)